Pathophysiology and current understanding of degenerative disc disease

Abstract

Degenerative disc disease is a global health concern caused by a combination of genetic, mechanical, metabolic, and environmental factors that progressively disrupt the structure and function of intervertebral discs. The underlying pathophysiology of the condition involves the breakdown of the extracellular matrix, cellular aging, oxidative stress, and persistent inflammation, all of which are driven by cytokines like interleukin 1β, tumor necrosis factor-alpha, and interleukin 6. These processes are regulated by several signaling pathways, such as nuclear factor kappa B, mitogen-activated protein kinase, and Wnt/β-catenin, which contribute to matrix degradation, dehydration, and loss of disc height. Epidemiological studies show that factors like obesity, smoking, and diabetes can accelerate the progression of the disease. While current treatments, both conservative and surgical, mainly focus on symptom relief, they do not halt or reverse the degeneration process. On the other hand, recent advancements in molecular biology and regenerative medicine offer promising new treatment options. Strategies like mesenchymal stem cell therapy, biomaterial scaffolds, and gene therapies aim to restore disc homeostasis by encouraging matrix repair and reducing harmful breakdown processes. Despite encouraging preclinical results, clinical application remains limited by challenges related to cell survival, delivery techniques, and long-term outcomes. Integrating molecular, biomechanical, and regenerative approaches could lead to more effective treatments, including potential disc regeneration.

Key Words: Intervertebral disc; Degenerative disc disease; Degeneration; Cytokines; Cellular senescence; Treatment

Core Tip: Degenerative disc disease is a multifactorial condition caused by genetic, mechanical, metabolic, and environmental factors that disrupt disc homeostasis, resulting in chronic back pain and disability. Key pathological mechanisms include extracellular matrix degradation, oxidative stress, cellular senescence, and inflammation mediated by cytokines such as interleukin 1β, tumor necrosis factor-alpha, and interleukin 6 via several signaling pathways. While current treatments primarily address symptoms, emerging regenerative approaches, including mesenchymal stem cell therapy, biomaterial scaffolds, and gene-based interventions, aim to restore disc structure and function. Integrating molecular, biomechanical, and regenerative insights offers promise for achieving true biological disc repair.

INTRODUCTION

Degenerative disc disease (DDD) and its associated back pain represent a major and growing global health burden[1,2]. These conditions are chronic, multifactorial, and contribute substantially to morbidity and disability across diverse populations. Although the term degeneration may imply a simple wear-and-tear process, the underlying pathophysiology of DDD is considerably more complex. It reflects a dynamic interplay between mechanical loading, genetic susceptibility, metabolic and nutritional factors, and broader environmental influences. Together, these elements progressively disrupt the structure and function of the intervertebral disc (IVD), ultimately compromising the biomechanical stability of the spinal segment[3].

Traditionally viewed as a passive “shock absorber” between vertebral bodies, the IVD is now recognized as a metabolically active tissue that maintains homeostasis through tightly regulated cellular and extracellular matrix (ECM) processes[3]. When this balance is disturbed, degenerative changes ensue, leading to a spectrum of clinical manifestations. Patients with DDD may experience axial back pain originating from the spinal column or develop more complex syndromes such as spinal stenosis (narrowing of the spinal canal), myelopathy (spinal cord dysfunction caused by disc-related compression), or radiculopathy (nerve-root compression)[3-5]. These symptoms not only impose a substantial clinical burden but also reflect significant structural deterioration that can contribute to chronic spinal instability and long-term functional decline. Importantly, the impact of DDD is not limited to older adults; younger and working-age individuals may also experience marked reductions in quality of life, productivity, and daily functioning[2].

Despite extensive research, key uncertainties remain regarding the earliest molecular and cellular events that initiate IVD degeneration, the mechanisms linking structural IVD damage to symptomatic pain, and the most effective strategies to halt or reverse degeneration[1,4,5]. Conventional management has largely focused on symptom control through analgesics, physical therapy, and surgical interventions, approaches that often fail to address the underlying pathology[4,5]. However, recent advances in molecular diagnostics, imaging technologies, and regenerative medicine are beginning to clarify the biochemical and cellular mechanisms driving IVD degeneration. These developments are opening the door to more targeted, disease-modifying therapies that hold promise for transforming the clinical management of IVD degeneration[5-7]. The aim of this article was to provide an overview of the mechanisms, risk factors, current treatments, and emerging regenerative strategies for IVD degeneration, highlighting existing challenges and future therapeutic directions.

ANATOMY OF THE IVD

To understand the mechanisms underlying IVD degeneration, it is essential to first consider the normal anatomy and physiology of the IVD (Table 1). The IVD comprises three principal components, the annulus fibrosus (AF), nucleus pulposus (NP), and cartilaginous endplates (CEPs) at the superior and inferior part of the IVD. Each of these components contribute to distinct structural and biomechanical functions[8].

Table 1 Summary of normal anatomy and physiology of intervertebral disc.

Component	Structure	Primary function	Key features
AF	Concentric collagen lamellae; outer AF rich in type I collagen, inner AF rich in type II	Resists tensile/shear forces; contains NP	Limited vascularity; provides circumferential strength
NP	Hydrated, proteoglycan-rich gel (high aggrecan/GAG content)	Generates hydrostatic pressure; absorbs compressive loads	Completely avascular; maintains hydration-dependent load distribution
CEPs	Thin hyaline cartilage layers between disc and vertebrae	Nutrient and metabolite diffusion	Primary route of nutrient/waste exchange via subchondral capillaries
Vascular supply	NP and inner AF avascular; CEP-adjacent capillary network	Diffusion-based nutrient support	Low metabolic turnover; vulnerable to hypoxia and nutrient limitation
Cellular activity	Sparse disc cells regulating ECM turnover	Maintains ECM integrity and hydration	Low metabolic reserve; sensitive to mechanical and metabolic stress
Biomechanical function	Integrated AF-NP-CEP system	Distributes compressive, tensile, and shear forces	Depends on hydration, ECM turnover, and cell viability
Vulnerabilities	Avascular, hypoxic microenvironment	Predisposed to degeneration if homeostasis fails	Risk increases with aging, mechanical load, and metabolic stress

AF: Annulus fibrosus; NP: Nucleus pulposus; CEP: Terminal endplate; GAG: Glycosaminoglycans; ECM: Extracellular matrix.

The AF forms the outer boundary of the IVD and consists of 15-25 concentric lamellae of collagen fibers arranged in an oblique, alternating pattern. This unique architecture in which collagen type I predominates in the outer AF and collagen type II becomes more abundant toward the inner AF and provides the IVD with exceptional resistance to tensile, torsional, and shear forces. The highly organized lamellar structure allows the AF to withstand multidirectional loading while simultaneously restraining the NP within the IVD space. The AF also contains a sparse population of fibroblast-like cells that synthesize and maintain the collagen-rich ECM[2,8,9].

Enclosed by the AF, the NP is a hydrated, gelatinous core responsible for bearing compressive loads. Its biomechanical properties arise from its high concentration of proteoglycans, particularly aggrecan, whose glycosaminoglycan (GAG) chains attract and retain large amounts of water[1,2]. This hydrophilic matrix enables the NP to generate hydrostatic pressure under load, allowing the IVD to distribute compressive forces evenly across the spinal motion segment. The NP contains chondrocyte-like cells of notochordal or mature IVD origin, depending on age, actively maintaining the proteoglycan-rich ECM[8,9].

The CEPs form a thin layer of hyaline cartilage at the interface between the IVD and the adjacent vertebral bodies[2-4]. Although often overlooked, the CEPs are essential for IVD health: They anchor the AF and NP to the vertebrae, help transmit compressive forces, and crucially regulate metabolic exchange. Because the IVD is largely avascular, the CEPs serve as the primary gateway for diffusion of oxygen, glucose, and other nutrients from capillaries in the subchondral bone as well as the removal of metabolic by-products such as lactate. CEP permeability and integrity therefore play a central role in sustaining IVD cell viability[8,9].

An important feature of the IVD is its intrinsic avascularity. While the outer AF may contain a limited number of small blood vessels, the NP and inner AF lack direct vascularization entirely. Instead, IVD cells rely on passive diffusion across the CEPs, a process driven by concentration gradients and influenced by mechanical loading. Fluctuations in loading, specifically the diurnal cycle of compression and decompression, facilitate fluid flow, nutrient supply, and waste removal. Under normal physiological conditions, these processes maintain IVD hydration, osmotic balance, cellular metabolic activity, and ECM turnover[6-8].

Although IVD cells are sparse, constituting only 1% of the total volume of the IVD, they are metabolically active and tightly regulate ECM homeostasis. They orchestrate a delicate balance between anabolic processes (synthesis of proteoglycans and collagen) and catabolic processes (matrix degradation mediated by matrix metalloproteinases and aggrecanases). Proteoglycans maintain the osmotic properties of the tissue, collagen fibers confer tensile and structural integrity, and IVD cells constantly remodel the ECM in response to mechanical and biochemical cues. This dynamic equilibrium is essential for normal IVD function.

However, this finely tuned homeostasis is inherently fragile[9,10]. The avascularity of the IVD imposes strict metabolic constraints including limited nutrient availability, low oxygen tension, and accumulation of acidic waste products. These conditions create a chronically hypoxic and glycolysis-dependent microenvironment in which IVD cells must operate at the edge of their metabolic capacity. With aging microdamage to the CEPs, progressive sclerosis of the subchondral bone, and reduced CEP permeability further compromise nutrient diffusion. At the same time cumulative mechanical loading, repetitive torsion, and microtrauma increase ECM turnover demands[10,11]. When these stressors exceed the ability of the IVD to repair and maintain its matrix, the balance shifts from anabolic to catabolic activity. Proteoglycan loss reduces NP hydration and hydrostatic pressure, collagen fibers in the AF become disorganized, and microfissures develop. IVD cells adopt a senescent or inflammatory phenotype, producing proinflammatory cytokines, degradative enzymes, and reactive oxygen species (ROS). Together, these changes reduce the reparative capacity of the IVD and predispose it to degeneration[9-13].

MULTIFACETED ORIGINS OF IVD DEGENERATION

IVD degeneration does not arise from a single cause but results from the convergence of multiple pathogenic pathways. Although mechanical stress is often a key initiating factor in the degenerative process, it does not act in isolation[11]. Instead, degeneration reflects a multifactorial interplay of biochemical imbalances, inflammatory mediators, genetic predispositions, nutritional and metabolic disturbances, and age-related cellular changes, each undermining the capacity of the IVD for repair and homeostasis[11-15]. Understanding these interconnected mechanisms is essential for elucidating the pathophysiology of IVD degeneration and for developing targeted, disease-modifying interventions[16]. A summary of these multifactorial influences is provided in Table 2.

Table 2 Multifactorial mechanisms of intervertebral disc degeneration.

Category	Key mechanisms	Consequences for IVD	Representative factors
Mechanical stress and load	Repetitive microtrauma to AF and NP. Collagen/elastin disorganization. Loss of NP hydration. Altered biomechanics → increased shear forces	Decreased disc height. Structural failure. Instability. Herniation and nerve compression	Heavy labor, torsion, bending, vibration exposure
Genetic and environmental factors	SNPs affecting ECM proteins and inflammatory mediators. Altered ECM synthesis or stability. Epigenetic changes due to lifestyle factors	Early weakening of ECM. Increased inflammatory signaling. Catabolic microenvironment	Gene variants (COL1A1, COL9A2, ACAN, IL-1, IL-6), smoking, obesity, vibration, repetitive loading
Nutrition and metabolism	Impaired nutrient diffusion across CEP. Local hypoxia + acidic microenvironment. Accumulation of AGEs. Oxidative stress and systemic metabolic dysregulation	Reduced cell viability. Inhibited proteoglycan synthesis. ECM stiffening. Impaired permeability and degeneration	Endplate calcification, atherosclerosis, diabetes, metabolic syndrome, obesity
Cellular senescence	Oxidative stress, DNA damage, mitochondrial dysfunction. SASP production: Proinflammatory cytokines, MMPs, ADAMTS. NF-κB and p38 MAPK activation	ECM degradation. Increased inflammation. Loss of regenerative capacity. Accumulation of non-functional cells	Increased ROS, mitochondrial dysfunction, SASP factors (IL-1β, IL-6, TNF-α), MMPs, ADAMTS
Aging and microenvironment	Loss of proteoglycans and GAGs → decreased hydration. Increased collagen cross-linking, fragmentation. CEP calcification and sclerosis. Accumulation of waste products	Reduced elasticity and load-distribution. Hypoxia and acidity. Increased apoptosis and catabolism. Progressive irreversible degeneration	Age-related CEP thickening, decreased metabolic activity, reduced nutrient diffusion
Lifestyle and comorbidities	Smoking-induced hypoxia. Obesity increasing axial load. Sedentary behavior reducing beneficial mechanical stimuli. Metabolic disorders increasing AGEs	Oxidative stress. Matrix degradation. Increased stiffness and reduced tensile strength. Accelerated degeneration	Smoking, obesity, poor posture, inactivity, diabetes

IVD: Intervertebral disc; AF: Annulus fibrosus; NP: Nucleus pulposus; CEP: Terminal endplate; ECM: Extracellular matrix; SNPs: Single-nucleotide polymorphisms; COL: Collagen; ACAN: Aggrecan; IL: Interleukins; AGEs: Advanced glycosylation end products; ROS: Reactive oxygen species; SASP: Senescence-associated secretory phenotype; TNF-α: Tumor necrosis factor alpha; MMPs: Matrix metalloproteinases; ADAMTS: A disintegrin and metalloproteinase with thrombospondin motifs; MAPK: Mitogen-activated protein kinase; GAG: Glycosaminoglycan; NF-κB: Nuclear factor kappa B.

Mechanical strain and load

Abnormal or sustained mechanical loading, such as heavy manual labor, repetitive flexion and rotation, or exposure to vibration, can impose continuous microtrauma on the IVD[3-5]. Over time these repetitive stresses compromise the structural integrity of the AF, leading to microfissures and disorganization of collagen and elastin fibers within the ECM. As the NP gradually loses its gel-like consistency and water-binding capacity, its ability to distribute compressive forces diminishes. The consequent loss of IVD height alters spinal biomechanics, increasing shear forces and abnormal loading on adjacent vertebrae and facet joints[6-9]. These maladaptive mechanical changes perpetuate a cycle of instability and cellular stress that accelerates degeneration in neighboring IVDs. Ultimately, the process may culminate in gross structural failure, IVD herniation, or nerve-root compression, manifesting clinically as pain, reduced mobility, or neurological deficits[17-19].

Genetic and environmental aspects

Genetic predisposition is a major determinant of individual susceptibility to IVD degeneration. Twin and family-based studies estimate that heritability accounts for 50%-70% of the variance in IVD degeneration, highlighting the substantial contribution of inherited factors[20]. This estimate is derived primarily from classical twin studies conducted in the late 1990s and early 2000s, most notably magnetic resonance imaging (MRI)-based investigations comparing monozygotic and dizygotic twins[21-23]. These studies consistently demonstrated substantially higher concordance rates and greater similarity in the extent and distribution of IVD degeneration among monozygotic twins even when lifetime occupational loading, physical activity, and other environmental exposures differed markedly between co-twins. Such findings provided strong evidence that inherited factors exert a dominant influence on IVD morphology, biochemical composition, and susceptibility to degenerative change[24,25].

Subsequent population-based, familial, and genome-wide association studies have largely corroborated the importance of genetic determinants while also refining earlier heritability estimates. More recent data indicate that the magnitude of genetic influence is not uniform but varies according to spinal level (cervical vs lumbar), age and sex of the studied population, imaging modality and grading system used, and whether degeneration is defined radiologically or by clinical symptomatology. Accordingly, reported heritability estimates span a broader range, from moderate to high, rather than converging on a single fixed value[21,25-27].

The current body of evidence supports a major but not exclusive role for genetic factors in the development of IVD degeneration. The frequently cited 50%-70% heritability should therefore be interpreted as a synthesis of foundational twin studies that established genetic influence rather than as an absolute estimate applicable across all populations, disease stages, and methodological contexts. This perspective aligns with contemporary models that emphasize gene-environment interactions as central drivers of degenerative IVD pathology[23-26].

Numerous genetic association studies have identified polymorphisms in genes involved in structural integrity, matrix metabolism, and inflammatory signaling. Variants in collagen genes, including COL1A1, COL9A2, COL2A1, and COL11A1, alter the composition or stability of the AF and NP, reducing the ability of the IVD to resist tensile and compressive loads. Mutations in aggrecan can decrease the size, sulphation, or abundance of aggrecan molecules, directly impairing the capacity of the NP to retain water and generate hydrostatic pressure. In addition, polymorphisms in regulatory genes such as interleukin-1α (IL-1α), IL-1β, IL-6, tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases (MMP-3, MMP-9) contribute to heightened baseline inflammation and increased ECM degradation[20,28].

Several of these variants are thought to predispose individuals to early-onset degeneration by shifting the IVD microenvironment toward catabolism, inflammation, or impaired matrix synthesis. For example, the IL-1α polymorphism has been associated with increased production of IL-1, a cytokine that potently upregulates aggrecanases and MMPs while suppressing proteoglycan synthesis[29]. Similarly, the COL9A2 Trp2 allele has been linked with reduced collagen IX content in the NP, weakening the structural network that stabilizes proteoglycans within the ECM[18-20]. These genetic alterations may not cause degeneration in isolation, but they create a biologically vulnerable IVD that is more susceptible to damage under mechanical or metabolic stress. However, genetic predisposition alone does not fully account for the variability in disease onset, severity, or progression. Many individuals with high-risk genotypes never develop clinically significant DDD, whereas others with no known polymorphisms experience early and aggressive degeneration. This discrepancy reflects the critical influence of environmental and lifestyle factors, which modulate biological pathways that affect IVD homeostasis[20,28,30].

Occupational loading, repetitive bending and lifting, whole-body vibration (heavy machinery operators), smoking, obesity, sedentary behavior, and metabolic syndrome all contribute to IVD degeneration through mechanical, biochemical, or systemic pathways. Importantly, these factors do not act independently of genetics[19,20]. Instead, they influence gene expression through epigenetic mechanisms including: DNA methylation, which can silence or activate specific genes; histone modifications, which alter chromatin accessibility; and non-coding RNAs (microRNAs and long non-coding RNAs), which regulate mRNA stability and translation[20,28,30]. Recent studies have provided direct evidence that aberrant DNA methylation patterns are closely linked to the degenerative phenotype of IVD cells. Genome-wide and candidate-gene analyses have demonstrated hypermethylation of anabolic genes, such as ACAN (gene for aggrecan) and COL2A1 (gene for collagen) in NP tissue, accompanied by reduced gene expression and impaired ECM synthesis. Conversely, hypomethylation of catabolic and inflammatory genes, including MMP-3, MMP-9, and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS4 and ADAMTS-5), has been associated with their upregulated expression, promoting proteoglycan breakdown and matrix disorganization in degenerated IVDs[31-34].

Cigarette smoke, for example, induces oxidative stress and reduces microvascular perfusion of the CEP. At the molecular level it can alter methylation patterns in genes encoding matrix-degrading enzymes such as MMP-3 or ADAMTS-5, increasing their expression while simultaneously suppressing aggrecan production. Experimental studies have shown that nicotine exposure induces DNA hypomethylation at promoter regions of catabolic genes while increasing methylation of ECM-related genes, thereby shifting the balance toward matrix degradation and impaired IVD hydration[35,36].

Chronic mechanical overload has similarly been shown to influence the methylation state of genes linked to inflammation and apoptosis, driving IVD cells toward a senescent or inflammatory phenotype[37-39]. In addition to DNA methylation, histone modifications have emerged as key regulators of IVD cell behavior. Increased histone acetylation at promoters of inflammatory cytokines such as IL-1β and TNF-α has been reported in degenerated IVDs, facilitating transcriptional activation. Conversely, reduced levels of repressive histone marks (H3K27me3) at catabolic gene loci have been associated with sustained inflammatory signaling and accelerated ECM degradation. Dysregulation of histone-modifying enzymes, including histone deacetylases and histone methyltransferases, further contributes to altered chromatin states and pathological gene expression in DDD[32,40,41].

Obesity and metabolic syndrome add further stressors through systemic low-grade inflammation, elevated cytokines, and altered lipid metabolism, all of which affect epigenetic regulation of IVD cell activity. Adipokines such as leptin and resistin have been shown to modulate DNA methylation and histone acetylation in IVD cells, enhancing inflammatory responses and promoting cellular senescence[42,43].

Thus, IVD degeneration is best understood as a multifactorial disorder resulting from continuous interactions between inherited and acquired factors. Genetic variants may determine the baseline vulnerability of the IVD while environmental exposures shape the trajectory of disease expression through epigenetic programming. The dynamic interplay of these influences underscores why IVD degeneration can present across a wide spectrum from asymptomatic structural changes to severe, symptomatic degeneration requiring surgical intervention. Understanding these gene-environment interactions is crucial not only for identifying individuals at elevated risk but also for developing personalized prevention and treatment strategies. Emerging epigenetic biomarkers may enable patient stratification and early disease detection, and therapeutic modulation of epigenetic regulators, such as histone deacetylases inhibitors or targeted DNA methylation modifiers, represents a potential avenue for disease-modifying interventions in DDD[19,30]. Continued research in this area promises to refine risk prediction and inform precision-medicine approaches to IVD degeneration.

Nutritional and metabolic characteristics

The IVD is largely avascular structure. Cell survival and ECM maintenance depend on diffusion of nutrients and oxygen through the CEP[44,45]. This diffusion is highly sensitive to endplate permeability and the integrity of the vertebral microvasculature. When compromised through CEP calcification, microvascular atherosclerosis, or systemic hypoxia, the nutrient supply becomes inefficient. Metabolic by-products such as lactic acid accumulate, lowering extracellular pH and creating an acidic microenvironment that reduces cell viability, suppresses proteoglycan synthesis, and accelerates matrix degradation[45-47].

Systemic metabolic dysfunction further contributes to degeneration. Impaired glucose metabolism and insulin resistance, common in metabolic syndrome and diabetes, lead to oxidative stress and formation of advanced glycation end (AGEs) products[47,48]. AGEs induce irreversible collagen cross-linking, reducing tissue elasticity and impairing the mechanical and transport properties of the IVD. This stiffening further restricts nutrient diffusion, creating a self-reinforcing cycle of metabolic and structural decline[49,50]. Moreover, obesity-related chronic inflammation and excess production of proinflammatory cytokines and ROS accelerate IVD cell senescence and apoptosis. Collectively, these observations demonstrate that IVD degeneration is not merely a local mechanical failure but also a systemic metabolic disorder influenced by vascular health, nutritional status, and cellular energy metabolism[50-52].

Cellular senescence

Cellular senescence is a conserved response to intrinsic and extrinsic stressors that is characterized by irreversible growth arrest and profound phenotypic changes. In the IVD senescence contributes directly to aging and degeneration, diminishing the pool of functional cells and altering tissue homeostasis[53]. Oxidative stress, mitochondrial dysfunction, and persistent DNA damage are major drivers of premature senescence in NP and AF cells[54,55]. Senescent cells exhibit a senescence-associated secretory phenotype, marked by the release of proinflammatory cytokines (IL-1β, IL-6, TNF-α), chemokines, growth factors, and matrix-degrading enzymes such as MMPs and aggrecanases (such as ADAMTS)[54-57]. The senescence-associated secretory phenotype promotes ECM breakdown, particularly of proteoglycans such as aggrecan, impairs matrix synthesis, and perpetuates inflammation within the IVD. This creates a self-sustaining cycle of catabolism and inflammatory amplification that accelerates degenerative changes[56,57].

Oxidative stress further aggravates senescence by damaging mitochondria and DNA. Mitochondrial dysfunction not only reduces ATP production but also increases ROS generation, amplifying senescence signaling. Accumulation of senescent cells reduces the regenerative capacity of the IVD and compromises its ability to maintain ECM integrity[58,59]. Key signaling pathways such as nuclear factor kappa B and p38 mitogen-activated protein kinase regulate senescence-associated secretory phenotype expression and sustain the inflammatory milieu. Therapeutic strategies targeting these pathways, eliminating senescent cells (senolytics), or modulating their secretory activity (senomorphics) show promise for slowing or reversing degenerative processes[59-61].

Aging and microenvironmental changes

Aging is one of the most influential intrinsic drivers of IVD degeneration, profoundly affecting cellular composition and ECM organization[62]. With age the NP experiences a marked decline in proteoglycan and GAG content, reducing its water-binding capacity and compromising IVD turgor. Collagen fibers in both AF and NP undergo increased cross-linking, fragmentation, and disorganization, diminishing elasticity and mechanical resilience. Concurrently, CEPs gradually thicken, calcify, or become sclerotic, restricting nutrient transport to the avascular IVD cells. As the nutrient supply decreases, metabolic activity declines, waste accumulates, and the microenvironment becomes increasingly hypoxic and acidic, conditions that impair cell survival and matrix synthesis[51,52]. Functionally, the reduced ability of the IVD to resist compressive forces increases stiffness and susceptibility to fissuring, annular tears, and bulging under physiological load. Although early degenerative changes may appear during adolescence, the cumulative effects of age-related molecular and structural alterations lead to progressive and irreversible deterioration over time[53-55].

Lifestyle and comorbidity influences

Substantial epidemiological and clinical evidence demonstrates that lifestyle factors, such as smoking, obesity, sedentary behavior, poor posture, and metabolic disorders, significantly influence the onset and progression of IVD degeneration. Smoking causes vasoconstriction and reduces oxygen transport, exacerbating the already limited nutrient supply of the IVD. Nicotine and other toxins impair IVD cell metabolism and elevate oxidative stress, accelerating ECM degradation[4,6,63,64].

Obesity increases axial loading on the spine, intensifying mechanical stress while also promoting systemic low-grade inflammation that disrupts IVD homeostasis. Sedentary behavior and poor posture reduce spinal mobility and diminish the beneficial mechanical stimuli necessary to maintain IVD metabolism[49,64]. Metabolic disorders such as diabetes further exacerbate degeneration through increased AGE accumulation in collagen fibers, resulting in stiffer, more brittle ECM. Collectively, these factors interact across mechanical, biochemical, and inflammatory pathways to create a hostile microenvironment that accelerates degeneration and impairs regenerative potential[39,44,45].

MOLECULAR AND CELLULAR MECHANISMS OF DEGENERATION

Modern biochemical and molecular studies have revealed that IVD degeneration is driven by a complex cascade of cellular and extracellular events. Rather than representing a passive consequence of tissue wear, IVD degeneration is now understood as an active, multifactorial process involving mechanical overload, chronic inflammation, oxidative damage, and disrupted cell–matrix communication[65]. A central feature of degeneration is ECM breakdown, particularly the loss and fragmentation of proteoglycans. As proteoglycans diminish osmotic pressure falls, leading to dehydration, IVD shrinkage, and compromised mechanical performance. Degradation products may diffuse out of the IVD, and the collagen network becomes increasingly disorganized, further undermining biomechanical stability[53,54]. Enhanced catabolic activity is a hallmark of this process with upregulation of matrix-degrading enzymes including MMPs, aggrecanases of the ADAMTS family, and cathepsins. These enzymes cleave collagen and aggrecan, disrupting ECM architecture. Their degradation products in turn intensify local inflammatory signaling and reinforce a feed-forward loop of matrix destruction and cellular stress[55-58].

Discal cells along with vertebral endplate cells and infiltrating immune cells respond to and release proinflammatory cytokines such as IL-1β, TNF-α, IL-6, and IL-17. These cytokines promote the expression of catabolic enzymes, suppress anabolic matrix synthesis, and induce apoptosis or senescence in IVD cells. Persistent inflammation also facilitates aberrant nerve and blood vessel ingrowth into previously immune-privileged regions of the IVD, contributing both to neuroinflammation and pain generation[54,65,66].

The biochemical deterioration of the ECM leads directly to biomechanical failure. As hydration and IVD height decline, the NP loses its ability to generate hydrostatic pressure and distribute compressive forces evenly across the motion segment[4-6]. Load is increasingly shifted to the AF and posterior spinal elements. Concurrently, the metabolic and structural integrity of the IVD depends heavily on the adjacent CEPs. Degenerative changes such as endplate calcification, sclerosis, or microvascular insufficiency impair nutrient diffusion and waste clearance, reducing cell viability and exacerbating metabolic stress within the IVD[13,46,47]. Altered load distribution increases mechanical demand on the annular lamellae, endplates, facet joints, and surrounding ligaments. The AF experiences heightened tensile and shear forces, leading to collagen fiber disorganization, annular fissures, and eventually radial tears. Endplates may develop microfractures and further sclerosis, worsening nutritional impairment and reinforcing the degenerative cascade[52,56].

In response to these biomechanical changes, adjacent spinal structures undergo maladaptive remodeling. Facet joints bear greater compressive loads, resulting in hypertrophy and osteophyte formation. Ligaments, including the ligamentum flavum, may thicken under chronic mechanical stress, contributing to canal narrowing and spinal stenosis[61]. Paraspinal muscles may become imbalanced or overactive, amplifying mechanical instability. In advanced degeneration structural defects such as annular fissures or NP herniation create conduits for nociceptive nerve fibers and neovascularization into normally avascular IVD regions. This neoinnervation together with persistent production of cytokines such as TNF-α and IL-1β sensitizes nerve endings and produces discogenic pain, a hallmark clinical presentation of IVD degeneration[57,65].

Thus, IVD degeneration is not a passive wear-and-tear phenomenon but a dynamic, biologically active process driven by reciprocal interactions among mechanical forces, inflammatory pathways, oxidative stress, and dysregulated cell–matrix signaling. These interconnected mechanisms collectively sustain a self-perpetuating degenerative cycle. Advancing our understanding of these processes is fundamental to developing mechanobiologically informed therapies that restore IVD integrity, modulate pathological loading, and re-establish tissue homeostasis[61,62].

TRANSITION FROM DEGENERATION TO SYMPTOMATIC DISEASE

Importantly, not all instances of IVD degeneration produce clinical symptoms; a substantial proportion of degenerated IVDs remain asymptomatic throughout life. The progression from structural degeneration to symptomatic disease, manifesting as axial back pain, radiculopathy, or spinal stenosis, requires the convergence of additional biological and biomechanical factors beyond the degenerative changes themselves[18,19].

A key event in the development of symptoms is fissuring of the AF. These fissures permit leakage of proteoglycan fragments, inflammatory mediators, and alarmins (endogenous, constitutively expressed, chemotactic and immune activating proteins released as a consequence of cell injury or death or in response to immune stimulation) into peripheral IVD regions where they can activate nociceptors located in the outer AF, posterior longitudinal ligament, and surrounding soft tissues. This exposure sensitizes local nerve endings and creates a proinflammatory microenvironment that supports pain generation[17-19].

Another critical mechanism involves aberrant sensory nerve ingrowth and neovascularization. The healthy IVD is largely avascular and sparsely innervated, particularly within the NP and inner AF. During degeneration inflammatory cytokines (TNF-α, IL-1β, IL-6), neurotrophic factors (nerve growth factor, brain-derived neurotrophic factor), and matrix breakdown create permissive conditions for nociceptive nerve fibers and blood vessels to infiltrate deeper IVD regions. This neoinnervation of previously immune-privileged tissue is strongly associated with discogenic pain and heightened mechanical sensitivity[18].

Biomechanical instability also plays a pivotal role in symptom development. Loss of IVD height and NP pressurization alters load distribution across the spinal motion segment, leading to segmental hypermobility, increased strain on the AF, and excessive facet joint loading. These changes may provoke facetogenic pain, ligamentous tension, and reflex muscle spasm. Over time compensatory hypertrophy of the facet joints and thickening of the ligamentum flavum can contribute to central canal or foraminal narrowing, resulting in neurogenic claudication or radiculopathy[18,20,28]. Importantly, structural abnormalities observed on imaging do not reliably correlate with symptom severity. Many individuals with pronounced degenerative changes remain pain-free while others experience significant pain despite only mild imaging findings. This discrepancy highlights the central role of biochemical and microenvironmental factors, including local acidosis, oxidative stress, elevated lactate concentrations, and cytokine-driven sensitization, in modulating nociception and determining whether degeneration becomes symptomatic[17,18].

Therefore, the concept of IVD degeneration must be considered alongside the distinct but overlapping process of pain generation. Symptomatic DDD arises not simply from structural deterioration but from the integration of inflammatory, biochemical, neural, and biomechanical alterations that collectively contribute to pain, neurological symptoms, and functional impairment[13,17,18].

STRUCTURAL AND FUNCTIONAL CONSEQUENCES

Degenerative changes within the IVD have far-reaching structural and biomechanical consequences that extend well beyond the IVD itself, influencing adjacent ligaments, facet joints, vertebral endplates, neural structures, and the paraspinal musculature (Table 3). As IVD height diminishes, primarily due to progressive dehydration, loss of proteoglycans, and reduced hydrostatic pressure, the mechanical stability of the spinal motion segment becomes increasingly compromised. These changes alter the normal coupling between vertebral bodies, producing abnormal motion patterns, impaired shock absorption, and progressive segmental instability. Over time these maladaptive biomechanical shifts initiate a cascade of secondary osteoarthritic and degenerative changes throughout the motion segment[5,16].

Table 3 Key structural, biomechanical, and biochemical consequences of degenerative disc disease.

Entity	Primary changes	Main effects
Disc structure	Loss of height; dehydration; proteoglycan decline	Reduced hydrostatic pressure; impaired load absorption
Load redistribution	Increased loading of posterior elements	Facet joint degeneration; ligamentous strain
Spine stability	Segmental hypermobility; altered vertebral coupling	Mechanical instability; deformity (e.g., spondylolisthesis)
Spinal canal and foraminal anatomy	Ligamentum flavum hypertrophy; capsule thickening	Spinal/foraminal stenosis; nerve-root compression
Biochemical milieu	↑ Prostaglandins, nitric oxide, IL-1β, TNF-α	Nociceptor sensitization; chronic inflammation
Neural changes	Ingrowth of nociceptors + neovascularization	Discogenic pain; increased mechanical sensitivity
Overall outcome	Interaction of mechanical + inflammatory factors	Chronic pain, reduced mobility, progressive dysfunction

IL-1β: Interleukin 1beta; TNF-α: Tumor necrosis factor alpha.

One of the earliest consequences of IVD height loss is the redistribution of axial load from the NP to the posterior spinal elements. Increased mechanical stress on the facet joints accelerates articular cartilage wear, promotes synovial inflammation, and drives subchondral bone remodeling, ultimately culminating in facet joint osteoarthritis. Concurrently, chronic mechanical strain stimulates hypertrophy of the ligamentum flavum and thickening of the facet joint capsules[17]. These changes encroach upon the spinal canal and intervertebral foramina, contributing to central canal stenosis, lateral recess narrowing, and potential nerve-root compression. Progressive involvement of these structures may result in mechanical instability, spinal deformity (including spondylolisthesis or kyphotic alignment changes), and a gradual reduction in spinal mobility and functional capacity[4-6].

Pain generation in DDD arises from a complex interplay between structural deformation, mechanical overload, and biochemical sensitization. Mechanical collapse of the IVD reduces foraminal height and alters nerve-root tension, directly predisposing to radicular irritation. Simultaneously, degenerated IVD tissue releases inflammatory mediators, including prostaglandins, nitric oxide, ILs, and TNF-α, which sensitize nociceptors and amplify pain transmission. These cytokines also upregulate matrix-degrading enzymes and perpetuate a catabolic ECM environment, reinforcing the inflammatory loop[4,5].

A key event in the transition from structural degeneration to chronic pain is the neoinnervation of normally aneural IVD regions. Under healthy conditions nociceptive nerve fibers are restricted to the outer AF[6,19]. However, degeneration-associated ECM breakdown, increased expression of neurotrophic factors such as nerve growth factor and brain-derived neurotrophic factor, and accompanying neovascularization enable nociceptive fibers to penetrate the inner annulus and even the NP. This aberrant innervation renders the IVD highly sensitive to mechanical loading and inflammatory stimuli, creating a persistent pain generator[6,7,18,19].

Collectively, these structural, mechanical, and biochemical alterations transform the IVD from a resilient, load-bearing organ into a source of chronic inflammation, nociceptive signaling, and mechanical dysfunction. This integrated understanding underscores the complex, multifactorial pathophysiology underlying symptomatic IVD degeneration and highlights the necessity for therapeutic approaches that address both mechanical instability and inflammatory sensitization[18-20,28].

EPIDEMIOLOGY, DIAGNOSIS AND MANAGEMENT OF IVD

Epidemiological context

Low back pain represents a major global health burden and remains one of the leading causes of disability worldwide. Prevalence estimates vary across populations, but low back pain consistently ranks among the top reasons for medical consultation, accounting for the fifth most common cause of physician visits. Lifetime prevalence ranges from approximately 7.6% to 37.0%, depending on geographical region, age, and occupational exposure[2,67,68]. While most acute episodes resolve spontaneously within weeks, roughly 10% of patients develop chronic or recurrent symptoms that substantially diminish quality of life, work capacity, and daily functioning[1,2].

Degenerative changes within the IVD typically develop insidiously. Structural and biochemical alterations can appear as early as adolescence with epidemiological studies reporting early signs of IVD degeneration in up to 20% of adolescents and in nearly 90% of elderly individuals[4-6]. Despite this high prevalence, many IVDs showing advanced radiological degeneration remain clinically silent, illustrating the complex disconnect between imaging findings and symptom development[68]. This dissociation highlights the importance of integrating clinical, structural, and biochemical factors when assessing IVD degeneration[68,69].

Clinical manifestations

The clinical presentation of DDD is heterogeneous and depends on the degree, location, and pattern of IVD degeneration as well as secondary changes involving surrounding spinal structures[10,11]. Early in the degenerative process, patients may be asymptomatic with abnormalities detected incidentally on imaging conducted for unrelated conditions[68,69]. As degeneration progresses and IVD mechanics deteriorate, patients commonly develop axial spinal pain, typically chronic low back pain, characterized by stiffness, reduced flexibility, and discomfort exacerbated by sitting, bending, lifting, or prolonged static postures. This pain is largely mechanical in nature and reflects abnormal load transmission, microinstability, and facet joint strain within the degenerated motion segment[69,70]. With further IVD collapse and annular fissuring, nerve root irritation or compression may occur, producing radicular symptoms. These include radiating pain, paresthesia, numbness, or burning sensations following a dermatomal distribution, manifesting as sciatica in the lumbar spine or cervicobrachial neuralgia in the cervical spine. Severe root compression can result in motor weakness, reflex changes, or gait disturbance, necessitating urgent evaluation. Discogenic pain may also be referred to distant regions via shared segmental innervation, complicating clinical localization. Chronic nociceptive stimulation can lead to central sensitization, amplifying pain perception disproportionate to structural findings[2-10,71]. Inflammatory mediators released from degenerated IVD tissue, including IL-1β, TNF-α, and prostaglandins, contribute to biochemical sensitization of nociceptors. Simultaneously, neovascularization and the ingrowth of nociceptive nerve fibers into the normally aneural inner AF and NP sustain chronic inflammation and pain[69,71].

Secondary consequences such as paraspinal muscle spasm, reduced core stability, altered gait mechanics, and compensatory postural adaptations further restrict function and exacerbate symptoms. In advanced lumbar degeneration spinal canal stenosis may develop, presenting with neurogenic claudication, pain, numbness, or weakness in the lower limbs provoked by walking and relieved by spinal flexion. Cervical degeneration may lead to myelopathic features such as hand clumsiness, balance difficulties, and fine motor impairment due to spinal cord compression. Overall, the clinical manifestations of DDD arise from a multifaceted interplay of structural degeneration, mechanical dysfunction, inflammatory sensitization, and neural adaptation. Recognizing this complexity is essential for accurate diagnosis and personalized management[12,68-79].

Diagnostic evaluation

Diagnosis of DDD requires integration of clinical assessment, imaging, and in selected cases functional and biochemical tests[9,10]. A detailed patient history should explore pain characteristics, functional limitations, neurological symptoms, and aggravating or alleviating factors. Physical examination often reveals paraspinal tenderness, reduced spinal mobility, and pain provoked by flexion-extension or axial loading, suggesting segmental instability. However, clinical findings are non-specific and must be correlated with imaging results[69,70].

MRI is the gold standard for evaluating IVD degeneration. MRI provides detailed visualization of IVD hydration, morphology, annular integrity, and neural structures. Hallmark MRI features include: Loss of T2 signal intensity (IVD desiccation); reduced IVD height; annular fissures; bulging or herniation; and Modic changes in adjacent vertebral endplates, indicating marrow inflammation or sclerosis. Quantitative MRI methods, such as T2 mapping, T1ρ imaging, and diffusion tensor imaging, are increasingly valuable for detecting early biochemical alterations before structural changes become apparent[73-75].

CT is useful for evaluating osseous abnormalities, including endplate sclerosis, osteophytes, and facet degeneration, and is often employed when MRI is contraindicated. Plain radiographs can demonstrate IVD space narrowing, vacuum phenomenon, and alignment abnormalities although they lack soft-tissue detail[75].

Discography, while controversial, may be selectively used to identify discogenic pain when conventional imaging is inconclusive. Risks include infection and potential acceleration of IVD degeneration[76].

Emerging biomarkers, including collagen II fragments, aggrecan breakdown products, inflammatory mediators, and markers of oxidative stress, are being investigated to aid diagnosis and monitor progression. Advances in artificial intelligence-driven radiomics may soon enable integration of imaging, clinical, and genetic data to improve diagnostic accuracy and stratify patients more effectively[77,78].

Optimal diagnostic evaluation thus requires a multifaceted approach combining structural imaging, clinical interpretation, and increasingly molecular characterization[77-79].

Therapeutic approaches

The management of DDD is inherently multifaceted with the overarching goals of reducing pain, improving function, and limiting further degenerative progression. Treatment strategies are tailored to the severity of symptoms, the extent of structural damage, and the presence of neurological deficits[4,7]. Because DDD is a chronic and progressive condition, a stepwise, escalation-based approach, beginning with conservative measures and advancing to more invasive interventions when necessary, is widely recommended (Table 4).

Table 4 Therapeutic options in degenerative disc disease.

Category	Therapy	Main features	Benefits and limitations
Conservative management	Physical therapy. Lifestyle modifications (weight loss, smoking cessation, ergonomics)	Strengthens core and paraspinal muscles. Improves posture and flexibility	Reduces mechanical strain. First-line therapy. Requires adherence
	Lifestyle modifications (weight loss, smoking cessation, ergonomics)	Addresses modifiable risk factors	Slows degeneration. Non-invasive. Patient-dependent
	Pharmacological therapy (NSAIDs, muscle relaxants, analgesics)	NSAIDs ↓ COX activity and prostaglandins. Analgesics reduce pain	Short-term relief; risks include gastrointestinal, renal, cardiovascular side effects
Medical pain management	NSAIDs	Anti-inflammatory via COX inhibition	Short-term relief. Limited disc penetration. Systemic risks
	Opioids	Activate G-protein coupled receptor pathways → inhibit neurotransmission	Effective for severe pain. High risk of addiction and dependence
	Muscle relaxants	Reduce muscle spasm	Symptomatic relief. Sedation risk
	Epidural corticosteroid injections	Reduce inflammation via COX and arachidonic acid inhibition	Temporary relief. Systemic steroid effects. No long-term benefit
Emerging pharmacologic therapies	Pamidronate	Bisphosphonate inhibiting osteoclasts and bone turnover	Potential pain reduction. Investigational
	Abaloparatide	Osteoporosis drug shown to reduce IVD degeneration (animal models)	Experimental. No established human benefit
	Alpha-2-macroglobulin	Protease inhibitor targeting FAC	Under investigation for slowing degeneration
Surgical management	Discectomy and decompression	Removes herniated disc tissue → relieves nerve compression	Effective for stenosis/herniation. Does not halt degeneration
	Spinal fusion	Removes disc → inserts cage + hardware. Eliminates motion	Pain reduction. Decreases mobility. Adjacent segment disease
	Total disc replacement	Replaces disc with motion-preserving prosthesis	Preserves mobility. Modest benefits vs fusion. Long-term data limited
Biological and regenerative therapies	Platelet-rich plasma	Growth factors (PDGF, VEGF, IGF-1, TGF-β) stimulate ECM synthesis	Promising early results. Inconsistent human data. No standardized protocols available
	Stem cell therapies	Implantation of regenerative cells into disc to restore ECM and hydration	Early promise. Challenges: Cell survival; microenvironment; delivery
	Growth factor therapy (TGF-β, BMP-7)	Enhances matrix production	Experimental. Limited human evidence
	Gene therapy	Introduces genes to enhance matrix synthesis or reduce catabolism	Highly experimental. Delivery and safety challenge

NSAID: Nonsteroidal anti-inflammatory drugs; COX: Cyclooxygenase; IVD: Intervertebral disc; FAC: Fibronectin-aggrecan complex; PDGF: Platelet-derived growth factor; VEGF: Vascular endothelial growth factor; IGF-1: Insulin-like growth factor 1; TGF-β: Transforming growth factor-β; ECM: Extracellular matrix; BMP-7: Bone morphogenetic protein 7.

Conservative therapy remains the foundation of initial management. Key components include physical rehabilitation, pharmacological treatment, and lifestyle modification. Structured physiotherapy programs target strengthening of paraspinal and core musculature, improved flexibility, and postural re-education to enhance segmental stability and reduce abnormal mechanical loading[79,80]. Lifestyle interventions such as weight reduction, smoking cessation, and ergonomic adjustments address modifiable risk factors and can meaningfully slow degenerative progression. When these measures do not provide adequate symptom relief, more intensive treatments, including advanced pharmacological therapies or surgical intervention, may be indicated. Current clinical guidelines for chronic back pain and DDD primarily emphasize symptom control rather than disease modification. While medications and surgery can alleviate pain and improve function, they do not halt or reverse the underlying degenerative cascade. As a result there is increasing interest in biologically-oriented therapies that target the molecular and cellular mechanisms of IVD degeneration although further research is required to establish their long-term safety and efficacy[81-83].

For the medical management of DDD, nonsteroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and short courses of analgesics are commonly used to control pain and inflammation. NSAIDs act by inhibiting cyclooxygenase enzymes responsible for prostaglandin synthesis and the inflammatory response[84,85]. Although the limited vascularity of the IVD may restrict their penetration and local efficacy, NSAIDs generally provide short-term symptomatic relief and are widely accessible. Their use, however, is associated with gastrointestinal ulceration, cardiovascular risk, and renal impairment, especially with prolonged or high-dose therapy[83,84].

Prescription opioids may be considered when pain is refractory to non-opioid medications. These agents mimic endogenous opioid peptides and activate G-protein-coupled receptors to inhibit neurotransmitter release and reduce nociceptive transmission. While opioids can offer significant short-term relief, their use carries substantial risks, including dependence, tolerance, and addiction. Patients treated with opioids for chronic low back pain demonstrate higher rates of long-term use compared with those treated for other musculoskeletal conditions.

Epidural corticosteroid injections provide another option for short-term symptom relief by suppressing inflammation through inhibition of arachidonic acid release and cyclooxygenase-mediated pathways. Ongoing trials are investigating whether specific injection routes (e.g., transforaminal vs interlaminar) offer clinically superior outcomes. Nevertheless, corticosteroids may induce systemic side effects and do not produce durable pain reduction, limiting their long-term utility[85].

Several pharmacological agents used traditionally for systemic or skeletal disorders are now being explored for discogenic pain[85]. These include pamidronate, a bisphosphonate that reduces osteoclast activity and demonstrates potential analgesic effects by modulating endplate bone turnover, and abaloparatide, which is conventionally used for osteoporosis but has shown promise in animal models in reducing IVD degeneration. Alpha-2-macroglobulin is also under investigation for its ability to inhibit cartilage-degrading proteases that generate fibronectin-aggrecan complexes and degradation products associated with discogenic pain. Clinical trials are examining whether concentrated autologous alpha-2-macroglobulin injections can slow progressive IVD degeneration[85-87].

When conservative measures are no longer effective in controlling symptoms, surgical intervention is considered, particularly in patients with persistent severe low back pain or neurological compromise. Discectomy and decompression procedures aim to relieve neural compression from herniated IVDs or stenosis, and spinal fusion is used to stabilize motion segments rendered unstable by degeneration[88,89]. Fusion involves IVD removal, placement of an interbody cage to restore IVD height, and fixation with screws or rods to eliminate painful motion. Minimally invasive fusion techniques minimize muscle damage and recovery times but require specialized expertise. Although fusion can effectively relieve pain in selected patients, it reduces spinal mobility and may accelerate degeneration in adjacent segments. Furthermore, some patients continue to require opioid therapy even after successful fusion.

Total IVD replacement offers an alternative aimed at motion preservation. The procedure replaces the entire IVD with an implant consisting of metal endplates and a polymeric core[89,90]. Randomized trials comparing total IVD replacement with fusion show modest short-term benefits in pain, disability, and quality of life although differences are often not clinically substantial. Next-generation artificial IVDs are currently being evaluated to improve long-term durability and kinematic performance. Despite their widespread use, long-term evidence suggests that surgery provides limited benefit for many patients and does not arrest the underlying degenerative process[81,90-92].

Emerging diagnostic and therapeutic opportunities

Growing interest in biological and regenerative therapies reflects the need for strategies that address the pathophysiology of IVD degeneration rather than its symptoms. Emerging approaches include platelet-rich plasma (PRP), gene therapy, growth factor delivery [e.g., transforming growth factor-β (TGF-β), bone morphogenic protein-7 (BMP-7)], and cell-based therapies involving mesenchymal stromal cells (MSCs) or NP-derived cells to restore ECM production and IVD hydration[80,91].

PRP, derived from autologous blood, contains high concentrations of growth factors such as platelet-derived growth factor, TGF-β, vascular endothelial growth factor, and insulin growth factor-1, which promote ECM synthesis and IVD cell proliferation in vitro and in animal models. Some experimental studies report improved IVD height and matrix composition following PRP treatment. However, human clinical results remain inconsistent due to variability in PRP preparation, composition, and injection protocols. Stem cell-based therapies hold promise for biologically regenerating damaged tissue.

Current trials are investigating the safety and efficacy of bone marrow-derived MSCs, umbilical cord MSCs, and allogeneic cell preparations. The use of notochordal cells and induced pluripotent stem cells, which may more closely mimic native NP cell phenotypes, are also being explored[82-84]. Despite encouraging early findings, major challenges persist, including poor cell survival in the harsh, hypoxic, nutrient-deprived IVD environment, immunogenicity concerns, and inconsistency in cell delivery systems and supportive biomaterials. Although preclinical and early clinical results are promising, regenerative therapies remain experimental, and substantial work is required to refine cell sources, optimize biomaterials, improve delivery systems, and ensure long-term safety[82,92].

Effective long-term management of DDD requires an individualized, multimodal strategy that integrates mechanical stabilization, modulation of inflammation and pain, and when feasible, biological restoration of IVD structure and function. Future therapeutic paradigms will likely combine conventional treatments with regenerative and molecular interventions, aiming not only to relieve symptoms but also to alter the natural history of IVD degeneration itself[81,82,92].

With growing insight into the molecular mechanisms driving IVD degeneration, the diagnostic and therapeutic landscape is undergoing a notable shift. Advanced imaging modalities, particularly diffusion-weighted and T2-mapping MRI, now allow more precise assessment of IVD hydration, microstructural integrity, GAG content, and early biochemical changes that precede overt structural degeneration. Quantitative MRI biomarkers, such as apparent diffusion coefficient values and relaxation times, are emerging as promising tools for identifying early-stage degeneration, monitoring disease progression, and evaluating therapeutic responses[37].

On the therapeutic front, biologically-oriented strategies are moving from preclinical testing into early clinical application. These include MSC transplantation, gene therapy approaches targeting catabolic enzymes or proinflammatory cytokines, biomaterial-based scaffolds designed to restore mechanical and biochemical function, and senolytic therapies aimed at selectively eliminating senescent IVD cells[9,11]. Such innovations signal a paradigm shift away from traditional treatments, primarily analgesics, physical therapy, and surgical decompression towards regenerative and disease-modifying interventions that seek to halt or even reverse the degenerative cascade[5,6].

Regenerative and molecular therapies

Conventional conservative and surgical interventions for DDD focus on pain relief and functional restoration but do not arrest the underlying degenerative processes. Consequently, regenerative medicine has become a major research focus, aiming to restore IVD structure, cellularity, biomechanics, and homeostasis at a fundamental biological level[66].

MSC therapy is among the most extensively investigated regenerative strategies. MSCs derived from bone marrow, adipose tissue, or umbilical cord sources possess multipotent differentiation capacity and a potent paracrine secretory profile[62-64]. When delivered into degenerated IVDs, MSCs can differentiate toward NP-like phenotypes and secrete trophic factors that stimulate resident IVD cell proliferation, inhibit apoptosis, and enhance ECM synthesis[64-66]. In addition, MSCs exert strong immunomodulatory effects by suppressing key proinflammatory cytokines, most notably TNF-α and IL-1β, thereby reducing the chronic inflammatory milieu that perpetuates IVD degeneration. Early-phase clinical trials have reported improvements in IVD hydration (evident on T2-weighted MRI) along with reductions in pain and improvements in functional outcomes. However, long-term safety, optimal cell dosage, delivery techniques, and durability of therapeutic effects remain to be established in large, randomized controlled trials[66,67].

To optimize the harsh microenvironment of the degenerated IVD and improve cell survival, biomaterial-based scaffolds have been engineered to mimic the mechanical and biochemical properties of the native IVD[65,66]. Injectable hydrogels, collagen composites, alginate microspheres, and nanofibrous matrices provide three-dimensional structural support that facilitates cell retention, enhances nutrient diffusion, and allows controlled release of bioactive cues. Increasingly sophisticated hybrid scaffolds incorporate growth factors, chemokines, or gene vectors to amplify regenerative signaling and promote seamless integration with host tissue[66,67].

Parallel to these biomaterial advances, gene and molecular therapies are emerging as precision tools for restoring the catabolic-anabolic balance within the degenerating IVD. Cutting-edge approaches include clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9-mediated gene editing and viral vector-based gene delivery to selectively silence catabolic enzymes such as MMPs and ADAMTS or to reduce inflammatory mediators. Conversely, anabolic pathways can be enhanced through targeted overexpression of growth factors, including TGF-β, BMP-7, and insulin growth factor-1[47-49]. Small interfering RNA and microRNA-based therapeutics offer additional avenues to fine tune gene networks involved in ECM turnover, oxidative stress responses, and cellular senescence[61,62].

A particularly promising frontier involves exosome-based therapies. Exosomes, extracellular vesicles secreted by MSCs or NP cells, can deliver regenerative microRNAs, cytokines, and proteins directly to IVD cells without the risks associated with live-cell transplantation. Their acellular nature provides advantages in safety, scalability, storage, and regulatory approval, positioning them as an attractive next-generation therapeutic modality[61-71].

Collectively, these advances represent a paradigm shift from symptomatic management toward biologically targeted regeneration aimed at restoring IVD homeostasis, slowing disease progression, and preserving long-term spinal function. Continued progress in cell biology, biomaterials engineering, and molecular therapy development will be essential for translating these experimental approaches into clinically viable treatments for DDD[93-97].

Limitations and challenges of current regenerative treatments

Despite substantial advances in regenerative and molecular approaches for IVD degeneration, several biological, technical, and clinical limitations continue to hinder their widespread adoption in routine clinical practice. Although cell-based, biomaterial, and gene-targeted therapies aim to restore IVD homeostasis rather than merely alleviate symptoms, their long-term efficacy and safety remain incompletely understood[7,72,95].

One of the principal challenges is the hostile microenvironment of the degenerated IVD. The avascular nature of the IVD, combined with low oxygen tension, limited nutrient availability, acidic pH, and high mechanical stress, significantly compromises the survival, integration, and functional activity of transplanted cells[24,47,51]. MSCs, for example, show reduced viability and diminished anabolic activity when exposed to the hypoxic and inflammatory milieu characteristic of advanced degeneration. As a result many observed therapeutic effects may be transient or predominantly paracrine rather than truly regenerative[90,98,99].

Cell retention and delivery efficiency present additional technical barriers. Injectable cell suspensions may leak through annular fissures or fail to remain localized within the NP, particularly in structurally compromised IVDs. To address this biomaterial-based scaffolds and injectable hydrogels have been developed to improve cell retention and mechanical support. However, optimal scaffold composition, degradation kinetics, and long-term biomechanical compatibility with native IVD tissue have not yet been standardized, and inappropriate material properties may adversely affect physiological load transmission or integration with host tissue[65,71,95].

Another critical limitation concerns disease stage and patient selection. Regenerative strategies appear most effective in early or moderate stages of degeneration when IVD architecture is relatively preserved and a viable population of resident cells remains. In advanced IVD degeneration extensive ECM breakdown, endplate sclerosis, and IVD height loss markedly reduce regenerative potential, limiting the likelihood of meaningful structural restoration[7,72]. Nevertheless, many clinical studies include heterogeneous patient populations, complicating interpretation of outcomes and identification of patients most likely to benefit[82,99].

Immunological and safety considerations further constrain clinical application. Although MSCs are often considered immune-privileged, immune responses, altered differentiation, or unintended fibrotic or osteogenic transformation remain theoretical risks, particularly with allogeneic cell sources[98,99]. Gene-based therapies introduce additional concerns related to vector delivery, off-target genetic effects, long-term transgene expression, and regulatory oversight. While preclinical studies demonstrate promising modulation of inflammatory and catabolic pathways, robust long-term safety data in humans remain limited[72,95].

Clinical evidence supporting regenerative therapies for IVD degeneration is currently heterogeneous and largely preliminary. Many available studies are small, lack appropriate control groups, or rely primarily on subjective outcome measures such as pain and disability scores. Importantly, symptomatic improvement is not always accompanied by clear evidence of IVD regeneration on imaging, raising questions regarding the underlying mechanisms of action and durability of therapeutic benefit[99,100]. Moreover, long-term follow-up data extending beyond 2-5 years are scarce.

Finally, economic, regulatory, and standardization challenges must be considered. Cell-based and gene-based therapies are costly, technically complex, and subject to stringent regulatory requirements, potentially limiting accessibility even if clinical efficacy is established. The absence of standardized manufacturing protocols, dosing regimens, delivery techniques, and outcome measures further complicates comparison across studies and delays clinical translation[72,93].

While regenerative treatments for IVD degeneration hold considerable promise, their clinical application is currently constrained by the biological limitations of the IVD microenvironment, technical delivery challenges, incomplete understanding of long-term safety, and variability in clinical outcomes. Addressing these challenges will require well-designed randomized controlled trials, improved patient stratification, optimization of biomaterials and delivery systems, and integration of regenerative strategies with biomechanical and lifestyle interventions to achieve durable, disease-modifying outcomes[95,98-100].

FUTURE PERSPECTIVES

Despite major advances in elucidating the molecular, cellular, and biomechanical mechanisms of IVD degeneration, translation into durable, disease-modifying therapies remains limited. Regenerative and molecular therapies should be evaluated not only for short-term symptom relief but also for their ability to stabilize IVD structure, preserve biomechanical function, and delay downstream spinal degeneration[64,95]. Another challenge is the lack of consensus on what constitutes therapeutic success in IVD degeneration. Complete IVD regeneration is often unrealistic; therefore, future strategies should focus on clinically meaningful goals such as slowing degeneration, partially restoring matrix homeostasis, preventing further IVD height loss, or reducing inflammatory and nociceptive signaling[95,97]. Defining realistic, measurable endpoints is essential for effective trial design, regulatory approval, and clinical implementation. Given the multifactorial nature of IVD degeneration and DDD, effective future therapies will likely require multimodal integration of biological, mechanical, and lifestyle-based interventions tailored to disease stage and patient phenotype. Progress towards precision medicine will depend on validated biomarkers, standardized intervention protocols, and long-term outcome datasets to guide targeted and durable clinical translation[64-67,95,97].

Firstly, standardization of regenerative and cell-based therapies is urgently needed. Current MSC-based studies vary widely in cell source, tissue origin, dose, expansion protocols, and delivery techniques, limiting comparability and regulatory progress[95,97]. Future trials should harmonize these parameters and require detailed reporting of cell phenotype, senescence status, and secretory profile as therapeutic effects appear largely paracrine rather than dependent on long-term engraftment. Delivery-related variables, including injection volume, pressure, needle gauge, and use of biomaterial carriers, must also be standardized to minimize IVD injury and improve cell retention[95,98].

Secondly, validated biomarkers are required for patient stratification and treatment monitoring. Promising candidates include quantitative MRI metrics, biochemical markers of matrix turnover, and inflammatory mediators[95,99]. However, biomarker research must progress beyond exploratory reporting towards formal qualification. Longitudinal validation and correlation with structural changes and clinically meaningful outcomes are essential to distinguish transient analgesic effects from true biological modification. Multimodal approaches integrating imaging, molecular profiling, and clinical phenotyping, potentially supported by artificial intelligence, represent a promising direction[95,97,100].

Thirdly, appropriate clinical endpoints for regenerative trials must be clearly defined. Many studies continue to rely primarily on patient-reported outcomes despite aiming for structural repair. Future trials should employ hierarchical endpoints combining quantitative imaging metrics with clinical measures. Expectations regarding the magnitude and timeline of regeneration must be realistic, focusing on stabilization or modest improvement rather than complete restoration of a healthy IVD[95,98].

Significant gaps remain in long-term surgical outcome data. Although spinal fusion and total disc replacement are widely performed, comparative evidence beyond 10 years is limited, particularly regarding adjacent segment degeneration, reoperation rates, functional durability, and opioid dependence. Prospective registries and extended follow-up of randomized cohorts are needed to inform evidence-based surgical decision-making and cost-effectiveness analyses[95,99,100].

Additionally, biological therapies must be integrated with biomechanical strategies. Regenerative interventions are unlikely to succeed without addressing mechanical overload, posture, muscle function, and segmental stability. Combined approaches incorporating targeted rehabilitation, load modification, or motion-preserving stabilization warrant systematic investigation. Greater attention should also be paid to vertebral endplate health as endplate sclerosis and impaired nutrient transport critically limit regenerative capacity[71,72,97].

Finally, regulatory and ethical considerations will play a decisive role in clinical translation. Clear manufacturing standards, quality control measures, and safety endpoints are essential, particularly for advanced therapies such as gene editing, exosome-based interventions, and senolytics. Early engagement with regulatory authorities and adaptive trial designs may facilitate safe and efficient translation[4,6,95].

Future progress requires a paradigm shift towards integrated, standardized, and biomarker-informed research with long-term clinical validation, enabling molecular and regenerative innovations to become effective disease-modifying therapies for DDD[59,61,95].

SUMMARY OF MAIN ARTICLE POINTS

IVD degeneration and DDD are prevalent, multifactorial clinical conditions that represent a major global cause of chronic back pain and disability. As outlined in this review, IVD degeneration is no longer seen as a passive, age-related wear-and-tear process but rather as an active, biologically driven disorder arising from complex interactions between mechanical loading, genetic susceptibility, metabolic disturbances, inflammation, and cellular aging[2-4,7].

The IVD, once regarded as a simple structural spacer, is now recognized as a metabolically active tissue whose homeostasis depends on tightly regulated cellular and ECM dynamics. A central theme of this article was the vulnerability of the IVD microenvironment. The avascularity, low oxygen tension, limited nutrient diffusion, and acidic metabolic conditions impose intrinsic constraints on cell viability and matrix maintenance[9,10]. Age-related endplate sclerosis, cumulative mechanical stress, and metabolic comorbidities further impair nutrient transport, shifting the balance from anabolic matrix synthesis towards catabolic degradation. Loss of proteoglycans, collagen disorganization, and reduced hydration lead to diminished IVD height, altered biomechanics, and progressive structural failure[4,12,13].

The review highlighted the multifaceted origins of IVD degeneration, emphasizing that mechanical overload alone is insufficient to explain disease progression[14,15,19]. Genetic factors play a substantial role with polymorphisms in collagen, aggrecan, and inflammatory pathway genes increasing susceptibility to early or accelerated degeneration. These inherited risks interact with environmental and lifestyle factors, such as smoking, obesity, occupational loading, and metabolic syndrome through epigenetic mechanisms that modulate gene expression and cellular behavior. As a result DDD exhibits marked heterogeneity in onset, severity, and clinical presentation[48,50-52,59,96].

At the cellular level inflammation, oxidative stress, and senescence are identified as key drivers of degeneration. Proinflammatory cytokines, including IL-1β, TNF-α, and IL-6, activate catabolic signaling pathways such as nuclear factor kappa B and mitogen-activated protein kinase, upregulating matrix-degrading enzymes while suppressing ECM synthesis. Senescent cells adopt a deleterious secretory phenotype that perpetuates inflammation, matrix breakdown, and pain sensitization. These biological processes form self-reinforcing feedback loops that sustain degeneration even in the absence of continued mechanical insult[67,95].

Importantly, the article distinguished structural degeneration from symptomatic disease. Many degenerated IVDs remain asymptomatic, and pain arises from additional mechanisms including annular fissuring, inflammatory mediator leakage, aberrant nerve ingrowth, neovascularization, and biomechanical instability[4,13,20]. This dissociation explains the poor correlation between imaging findings and clinical symptoms and underscores the need for integrated diagnostic and therapeutic approaches.

From a clinical perspective current treatments, ranging from conservative management to surgical intervention, primarily address symptoms rather than the underlying pathology[10,95,97]. While advances in imaging and molecular diagnostics improve early detection, truly disease-modifying therapies remain elusive. Emerging regenerative strategies, including MSCs therapy, biomaterial scaffolds, gene-based interventions, and exosome-mediated approaches, offer promise but face significant translational challenges related to cell survival, delivery, patient selection, and long-term efficacy[10,92,95,97].

Overall, this review underscored that IVD degeneration is a dynamic, systems-level disorder requiring multidisciplinary solutions. Progress towards effective, disease-modifying treatment will depend on integrating molecular biology, biomechanics, imaging, and regenerative medicine within well-designed, longitudinal clinical frameworks. Such integration is essential to reduce the global burden of degenerative spinal disease and move beyond symptomatic management towards true biological repair[93,94,98].

CONCLUSION

IVD degeneration and DDD are complex, multifactorial disorders resulting from the interaction of mechanical, genetic, biochemical, nutritional, and environmental factors. The IVD, once considered a passive mechanical spacer, is now recognized as a metabolically active tissue whose degeneration reflects both local and systemic dysfunction. While traditional treatments focus mainly on symptom relief and preservation of mobility, emerging regenerative and molecular therapies aim to address the underlying disease processes. A deeper understanding of IVD aging and degeneration will be essential for developing truly restorative therapies capable of reducing the global burden of spinal degenerative disease.